Cargando…
Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2
Currently, there is no treatment approved for COVID-19. Numerous drugs are being used in an empirical manner according to experience and availability. Studies demonstrating their efficacy and safety are still to be published. Thus, it is of vital importance for healthcare workers to be well informed...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier España, S.L.U.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346774/ https://www.ncbi.nlm.nih.gov/pubmed/32718715 http://dx.doi.org/10.1016/j.medcli.2020.06.019 |
_version_ | 1783556461122551808 |
---|---|
author | Herrera-Lasso Regás, Valeria Dordal Culla, María Teresa Lleonart Bellfill, Ramón |
author_facet | Herrera-Lasso Regás, Valeria Dordal Culla, María Teresa Lleonart Bellfill, Ramón |
author_sort | Herrera-Lasso Regás, Valeria |
collection | PubMed |
description | Currently, there is no treatment approved for COVID-19. Numerous drugs are being used in an empirical manner according to experience and availability. Studies demonstrating their efficacy and safety are still to be published. Thus, it is of vital importance for healthcare workers to be well informed and updated regarding possible immunological and non-immunological adverse effects regarding such treatments. In this narrative revision, the rationale use of these treatments in the SARS-CoV-2 infection is emphasized as well as their most frequently described adverse drug reactions. Drugs that are being essayed to counteract both clinical phases that are thought to take place in the severe stage of this disease are included; an initial phase where a viral infection prevails and a second phase where an inflammatory response takes over. Adverse reactions registered in the Pharmacovigilance Program of our hospital before the onset of this pandemic have also been included. |
format | Online Article Text |
id | pubmed-7346774 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier España, S.L.U. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73467742020-07-10 Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2 Herrera-Lasso Regás, Valeria Dordal Culla, María Teresa Lleonart Bellfill, Ramón Med Clin (Barc) Revisión Currently, there is no treatment approved for COVID-19. Numerous drugs are being used in an empirical manner according to experience and availability. Studies demonstrating their efficacy and safety are still to be published. Thus, it is of vital importance for healthcare workers to be well informed and updated regarding possible immunological and non-immunological adverse effects regarding such treatments. In this narrative revision, the rationale use of these treatments in the SARS-CoV-2 infection is emphasized as well as their most frequently described adverse drug reactions. Drugs that are being essayed to counteract both clinical phases that are thought to take place in the severe stage of this disease are included; an initial phase where a viral infection prevails and a second phase where an inflammatory response takes over. Adverse reactions registered in the Pharmacovigilance Program of our hospital before the onset of this pandemic have also been included. Elsevier España, S.L.U. 2020-11-27 2020-07-09 /pmc/articles/PMC7346774/ /pubmed/32718715 http://dx.doi.org/10.1016/j.medcli.2020.06.019 Text en © 2020 Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Revisión Herrera-Lasso Regás, Valeria Dordal Culla, María Teresa Lleonart Bellfill, Ramón Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2 |
title | Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2 |
title_full | Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2 |
title_fullStr | Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2 |
title_full_unstemmed | Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2 |
title_short | Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2 |
title_sort | reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por sars-cov-2 |
topic | Revisión |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346774/ https://www.ncbi.nlm.nih.gov/pubmed/32718715 http://dx.doi.org/10.1016/j.medcli.2020.06.019 |
work_keys_str_mv | AT herreralassoregasvaleria reaccionesadversasafarmacosutilizadoseneltratamientoespecificodelainfeccionporsarscov2 AT dordalcullamariateresa reaccionesadversasafarmacosutilizadoseneltratamientoespecificodelainfeccionporsarscov2 AT lleonartbellfillramon reaccionesadversasafarmacosutilizadoseneltratamientoespecificodelainfeccionporsarscov2 |